ArticlePloS one2021
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Modular (universal) CAR-T platformsFrontiers in immunology · 2024Pooled it
- Engineering a PD-L1-sensing synthetic receptor for programmable macrophage response.Journal of biological engineering · 2026Article
- Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Current Landscape of Modular CAR T Cells.International journal of molecular sciences · 2025Review
- Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.Frontiers in immunology · 2025Article
- Discovery and engineering of AiEvo2, a novel Cas12a nuclease for human gene editing applications.The Journal of biological chemistry · 2024Article
- TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.Frontiers in immunology · 2024Article
- Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.Immunological reviews · 2023Review
- A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2Cells · 2023Article
- B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?Science translational medicine · 2022Review
- Using the Power of Junctional Adhesion Molecules Combined with the Target of CAR-T to Inhibit Cancer Proliferation, Metastasis and Eradicate Tumors.Biomedicines · 2022Article
- CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma.Oncoimmunology · 2022Article
- Secretory co-factors in next-generation cellular therapies for cancer.Frontiers in immunology · 2022Review
- Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid LeukemiaMolecular cancer therapeutics · 2021Article
- CAR T-cell therapy in multiple myeloma: more room for improvement.Blood cancer journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy by using integrated technologies that simplify development and derisk clinical translation. We have developed a CAR-CD19 T cell that secretes a CD19-anti-Her2 bridging protein. This cell therapy strategy exploits the ability of CD19-targeting CAR T cells to interact with CD19 on normal B cells to drive expansion, persistence and fitness. The secreted bridging protein potently binds to Her2-positive tumor cells, mediating CAR-CD19 T cell cytotoxicity in vitro and in vivo. Because of its short half-life, the secreted bridging protein will selectively accumulate at the site of highest antigen expression, ie. at the tumor. Bridging proteins that bind to multiple different tumor antigens have been created. Therefore, antigen-bridging CAR-CD19 T cells incorporate critical attributes for successful solid tumor cell therapy. This platform can be exploited to attack tumor antigens on any cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.